Maria Lansang, MD
Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1235153008
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,449 of the $8,320 with a category attached, or 65.5%. Sanofi-aventis U.S. LLC accounts for 67.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $5,581 and has fallen 90.5% since, to $532 in 2025.
Across 37 payments — averaging $224.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$6K
- Novo Nordisk$649
- Xeris Pharmaceuticals, Inc.$293
- Medtronic$286
- BETA Bionics, Inc.$225
- Sequel Med Tech, LLC$218
- plus $1K from 10 others
Across 29 payments — averaging $6917.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$149K
- Abbott$49K
- Boehringer Ingelheim$2K
What the payments were for
- Speaking & faculty fees$5,44965%
- Food & beverage$2,70733%
- Education$451%
- Gifts$1191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 2 | $5,574 |
| Novo Nordisk | 11 | $649 |
| Xeris Pharmaceuticals, Inc. | 5 | $293 |
| Medtronic | 1 | $286 |
| BETA Bionics, Inc. | 1 | $225 |
| Sequel Med Tech, LLC | 3 | $218 |
| Tandem Diabetes Care, Inc. | 2 | $138 |
| Dexcom, Inc. | 2 | $133 |
| Cequr Corporation | 1 | $128 |
| Vertex | 1 | $120 |
| Mannkind Corporation | 2 | $119 |
| Insulet Corporation | 1 | $114 |
| Amgen | 1 | $111 |
| Acorda Therapeutics, Inc | 1 | $104 |
| Ascensia Diabetes Care US Inc. | 2 | $97 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$5,449
- APIDRA$5,449
- iLet Bionic Pancreas$676
- MINIMED 780G$286
- GVOKE PFS$128
- CeQur Simplicity$128
- DEXCOM G7 GSS (161)$125
- t:slim X2 insulin pump$121
- Saxenda$118
- Omnipod$114
- TWIIST$112
- TEPEZZA$111
- INBRIJA$104
How this compares
$8,320 in reported general payments places this provider in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $153,888 |
| TrulicityDulaglutide | 69 | $112,795 |
| MounjaroTirzepatide | 83 | $110,456 |
| JardianceEmpagliflozin | 54 | $63,448 |
| TradjentaLinagliptin | 48 | $47,054 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $23,305 |
| BaqsimiGlucagon | 38 | $21,912 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $19,426 |
| FarxigaDapagliflozin Propanediol | 20 | $18,662 |
| JanuviaSitagliptin Phosphate | 14 | $14,810 |
| Gvoke Hypopen 2-PackGlucagon | 18 | $12,646 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $11,042 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $10,143 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $10,143 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $9,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $649 | $153,888103 claims |
| MerckJanuvia | $12 | $14,81014 claims |
| Sanofi-aventis U.S. LLCLantus | $5,574 | $2,24815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cleveland
- Kevin PantaloneCleveland$1.2M
- Allan KennedyCleveland$245K
- Adi MehtaCleveland$120K
- Amir HamrahianCleveland$59K
- Bartolome BurgueraCleveland$52K
- Christian NasrCleveland$46K
- Robert ZimmermanCleveland$45K
- Mario SkugorCleveland$45K
- Bahauddin ArafahCleveland$25K
- Divya Yogi-MorrenCleveland$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.